Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9365561 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL1177489 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| Fumaric Acid SCHEMBL1178140 | 0.90 | SLC6A2 (0.46) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL20989306 | 0.79 | GPR119 (0.47) | CHRM2CHRM1CHRM3 | |
| SCHEMBL20958444 | 0.75 | NAAA (0.67) | — | |
| SCHEMBL20958272 | 0.75 | NAAA (0.67) | — | |
| SCHEMBL21047701 | 0.73 | NPC1 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20989320 | 0.72 | NAAA (0.57) | — | |
| SCHEMBL9366067 | 0.72 | SLC6A2 (0.55) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 | |
| SCHEMBL1177859 | 0.72 | SLC6A2 (0.55) | SLC6A2SLC6A3CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | claimed |
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | PETERS DAN | 2008-10-30 | — | — | US | claimed |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | DANPET AB (SE) | 2006-06-29 | — | — | US | claimed |
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-05-12 | — | — | US | disclosed |
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | disclosed |
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | PETERS DAN | 2008-10-30 | — | — | US | disclosed |
| US-7407970-B2 | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2008-08-05 | — | — | US | disclosed |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | DANPET AB (SE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269229-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC18A3, SLC6A2 | SLC6A2 3/4885SLC6A3 6/4885CHRM2 199/4885 |
| US-20060142331-A1 | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC18A3, SLC6A2 | SLC6A2 3/4885SLC6A3 6/4885CHRM2 199/4885 |
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | SLC6A2 3/4885SLC6A3 6/4885CHRM2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.